JP Morgan Chase’s Trillium Therapeutics Inc. TRIL Stock Holding History

JP Morgan Chase’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40,000	Closed	-$702K	–	7267
2021 Q3	$702K	Buy	+40,000	New	+$467K	﹤0.01%	4533
2021 Q1	–	Sell	-210,800	Closed	-$3.1M	–	6507
2020 Q4	$3.1M	Buy	+210,800	New	+$3.04M	﹤0.01%	3172

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

JP Morgan Chase's TRIL Position: Q4 2021 in Review

JP Morgan Chase sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,510,226 shares — an estimated $26.5M sold.

JP Morgan Chase first reported a position in TRIL in Q1 2016 and held it in 7 quarters. The position peaked at $26.5M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

JP Morgan Chase reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
JP Morgan Chase sold 1,510,226 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $26.5M.
JP Morgan Chase first reported a position in Trillium Therapeutics Inc. in Q1 2016 and held it in 7 quarters.
JP Morgan Chase's Trillium Therapeutics Inc. position peaked at $26.5M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.